
UAE Influenza Vaccines Report 2025-2026
4 Surprising Trends from Dubai's Top Hospitals
From GCC formulary strategy to European KOL engagement, our case studies showcase the depth and precision of BioNixus intelligence across the MENA & EMEA healthcare ecosystem.

4 Surprising Trends from Dubai's Top Hospitals

A BioNixus CNS case study showing six shifts reshaping neurology: post-COVID demand expansion, metabolic-inflammation, gut-brain therapies, sober neuroplastogens, digital therapeutics, and blood-based diagnostics.

The Gulf Cooperation Council (GCC) region is facing a significant increase in cancer incidence, with growth rates projected to be approximately double the global average between 2020 and 2025. While Saudi Arabia (KSA) currently maintains the highest number of diagnosed cases, neighboring countries like Qatar, the UAE, and Kuwait are expected to see even faster growth

As the complexity of care increases, the need for "Intelligence for Business Growth" has never been more urgent
Our team is actively conducting these research programmes. Results will be published shortly.
Tracking physician adoption patterns for key biologics and biosimilars across GCC formulary systems.
In-depth qualitative interviews with oncologists mapping referral pathways and unmet needs.
Evidence gap analysis and payer positioning for a specialty immunology product.
BioNixus has delivered intelligence across 12+ therapeutic areas and service types.
Don't see your market or therapeutic area covered? We design bespoke research programmes for pharma and biotech leaders across MENA and EMEA.